64Cu labeled ambasar-RGD2 for micro-PET imaging of integrin αvβ3expression

Current Radiopharmaceuticals

Volumn 4, Issue 1, 2011, Pages 68-74

  Cai, Hancheng ^a,b   Li, Zibo ^a   Huang, Chiun Wei ^a   Park, Ryan ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bifunctional chelator; Copper 64; PET; RGD

Indexed keywords

4 [[8 AMINO 3, 6, 10, 13, 16, 19 HEXAAZABICYCLO(6 6 6)ICOSANE 1 YLAMINO]METHYL]BENZOIC ACID; ARGINYLGLYCYLASPARTIC ACID; BENZOIC ACID DERIVATIVE; CHELATING AGENT; COPPER 64; DIMERIC ARGINYLGLYCYLASPARTIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG SYNTHESIS; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MASS SPECTROMETRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; RECEPTOR BLOCKING; XENOGRAFT;

EID: 79955685696     PISSN: 18744710     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874471011104010068     Document Type: Article

References (33)

1. Eckelman, W. C.; Reba, R. C.; Kelloff, G. J., Targeted imaging: animportant biomarker for understanding disease progression in theera of personalized medicine. Drug Discov. Today, 2008, 13, 748-759.
2. Agdeppa, E. D.; Spilker, M. E., A review of imaging agent development.Aaps. J., 2009, 11, 286-299.
3. Varner, J. A.; Cheresh, D. A., Tumor angiogenesis and the role ofvascular cell integrin alphavbeta3. Important Adv. Oncol., 1996, 69-87.
4. Cai, W.; Niu, G.; Chen, X., Imaging of integrins as biomarkers fortumor angiogenesis. Curr. Pharm. Des., 2008, 14, 2943-2973.
5. 64Cu-labeled RGD peptide. J.Nucl. Med., 2007, 48, 311-318.
6. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J., RGDbasedstrategies for selective delivery of therapeutics and imagingagents to the tumour vasculature. Drug Resist. Updat., 2005, 8,381-402.
7. Beer, A. J.; Schwaiger, M., Imaging of integrin alphavbeta3 expression.Cancer Metastasis. Rev., 2008, 27, 631-644.
8. Chen, X., Multimodality imaging of tumor integrin alphavbeta3expression. Mini Rev. Med. Chem., 2006, 6, 227-234.
9. Guccione, S.; Li, K. C.; Bednarski, M. D., Molecular imaging andtherapy directed at the neovasculature in pathologies. How imagingcan be incorporated into vascular-targeted delivery systems to generateactive therapeutic agents. IEEE Eng. Med. Biol. Mag., 2004,23, 50-56.
10. Liu, S., Radiolabeled cyclic RGD peptides as integrin alphavbeta3-targeted radiotracers: maximizing binding affinity via bivalency.Bioconjug. Chem., 2009, 20, 2199-213.
11. 3-integrin expression in vivo. Acc. Chem. Res.,2009, 42, 969-980.
12. Cai, W.; Chen, X., Multimodality molecular imaging of tumorangiogenesis. J. Nucl. Med., 2008, 49 Suppl 2, 113S-28S.
13. 3 expression.Front. Biosci., 2009, 14, 887-899.
14. Hooker, J. M., Modular strategies for PET imaging agents. Curr.Opin. Chem. Biol., 14, 105-111.
15. Anderson, C. J.; Ferdani, R., Copper-64 radiopharmaceuticals forPET imaging of cancer: advances in preclinical and clinical research.Cancer Biother. Radiopharm., 2009, 24, 379-393.
16. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J., Copperchelation chemistry and its role in copper radiopharmaceuticals.Curr. Pharm. Des., 2007, 13, 3-16.
17. Shokeen, M.; Anderson, C. J., Molecular imaging of cancer withcopper-64 radiopharmaceuticals and positron emission tomography(PET). Acc Chem Res 2009, 42, 832-41.
18. 64Cu-labeled RGDpeptide. Bioconjug. Chem., 2004, 15, 41-49.
19. 3-integrin expression. J. Nucl. Med., 2004, 45, 1776-83.
20. Smith, S. V., Molecular imaging with copper-64. J. Inorg. Biochem.,2004, 98, 1874-1901.
21. 64Cu-SarAr immunoconjugates. Proc.Natl. Acad. Sci., U S A 2007, 104, 17489-17493.
22. 64Cu radiolabelling. Dalton. Trans., 2009, 27, 5395-400.
23. 64Cu radiopharmaceuticals. Nucl. Med. Biol., 2010, 37, 57-65.
24. 3 Expression. Bioconjug. Chem., 2010,21, 1417-1424.
25. 64Cu-labeled dimeric RGD peptides. Mol. ImagingBiol., 2004, 6, 350-359.
26. 18F-FPRGD2): synthesisand microPET imaging of alphavbeta3 integrin expression. Eur. J.Nucl. Med. Mol. Imaging, 2007, 34, 1823-31.
27. 4 linkers. Eur. J. Nucl Med. Mol. Imaging, 2009, 36,1296-307.
28. 3 integrin expression. J. Nucl. Med.,2007, 48, 1162-1171.
29. 18F] Galacto-RGD positronemission tomography. Neuro. Oncol., 2009, 11, 861-870.
30. 18F-Galacto-RGD PET. J. Nucl. Med., 2008,49, 255-259.
31. 18F-FDG. J. Nucl. Med., 2008, 49, 22-29.
32. 18F-AH111585 in breast cancer patients.J. Nucl.Med., 2008, 49, 879-886.
33. 18F-AH111585 in healthy volunteers. J. Nucl.Med., 2008, 49, 1664-1667.